Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438561 | 1.00 | MAPK1 (0.40) | MAPK1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3428847 | 1.00 | MAPK1 (0.40) | MAPK1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3428782 | 0.88 | SIGMAR1 (0.38) | ALDH1A1KMT2AMEN1SIGMAR1GBA1 | |
| SCHEMBL9801193 | 0.86 | MAPK1 (0.39) | MAPK1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3429437 | 0.84 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL3428842 | 0.84 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL24802087 | 0.83 | SIGMAR1 (0.35) | KMT2AMEN1SIGMAR1GBA1HSD11B1 | |
| SCHEMBL25873415 | 0.83 | SIGMAR1 (0.35) | KMT2AMEN1SIGMAR1GBA1HSD11B1 | |
| SCHEMBL12439866 | 0.83 | SIGMAR1 (0.35) | KMT2AMEN1SIGMAR1GBA1HSD11B1 | |
| SCHEMBL24801839 | 0.82 | MEN1 (0.33) | KMT2AMEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | MAPK1 896/4885KDM4E 3366/4885ALDH1A1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.